On June 17, Synergy Pharmaceuticals Inc (NASDAQ:SGYP) announced positive results from the first Phase 3 Trial of plecanatide in patients with chronic idiopathic …
Canaccord Genuity analyst Corey Davis came out with a research report on Synergy Pharmaceuticals Inc (NASDAQ:SGYP) after the company announced positive top-line results from the …
In a research report issued today, Canaccord analyst Corey Davis initiated coverage on shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP), with a Buy rating and …
In a research report issued today, Canaccord Genuity analyst Corey Davis reiterated a Hold rating on Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) with a …
In a research note released yesterday, Cannacord Genuity analyst Corey Davis reaffirmed a Buy rating on Actavis (ACT) with a price target of …
In a research note released today, Canaccord analyst Corey Davis reiterated coverage with a Buy rating on shares of Salix Pharmaceuticals (SLXP) and a $161.00 price target, following yesterday’s news of a definitive merger agreement …
In a research report released Thursday, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Endo International (ENDPׁׂ) and a price target of $83.00 a share, representing a potential upside of …
In a research report issued Thursday, Canaccord analyst Corey Davis initiated coverage with a “Hold” rating on Teva Pharmaceutical Industries (TEVA) and a price target of $55.70 a share, based on the following: 1) valuation, …
In a research report released yesterday, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Salix Pharmaceuticals (SLXP) and a price target of $145.00 a share, representing a potential upside of …
In a research report released today, Canaccord analyst Corey Davis initiated coverage with a “Buy” rating on Pacira Pharmaceuticals (PCRX) and a price target of $109.00 a share, representing a potential upside of …
